Mouse Models of Human Cancer database

ATCC Appoints Dr. Alfredo Molinolo to Its Board of Directors

Retrieved on: 
Thursday, November 2, 2023
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Genetics, Moores Cancer Center, Biorepository, DVM, Faculty of Medical Sciences, University of Buenos Aires, Head, Publication, Doctor of Philosophy, National Institute of Dental and Craniofacial Research, Hospital Rivadavia, HNSCC, Mouse Models of Human Cancer database, Medicine, Breast cancer, Medical research, University, University of California, San Diego, Collection, Breast, Bangladesh Technical Education Board, Neck, Management, Pathology, ATCC, MD, Biology, Cancer

“Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.

Key Points: 
  • “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
  • Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
  • Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
  • “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

Retrieved on: 
Thursday, August 17, 2023
KRAS, Research, Cysteine, Lung, CYPA, Protein, RAS, Mouse Models of Human Cancer database, Patient, Manuscript, Memorial Sloan Kettering Cancer Center, Cancer, Conference, Pharmaceutical industry, Science

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Science. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from Memorial Sloan Kettering Cancer Center.

Key Points: 
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from Memorial Sloan Kettering Cancer Center.
  • The paper describes the Revolution Medicines tri-complex inhibitor approach to developing novel small molecules with high affinity and selectivity for the active state of mutant RAS, or RAS(ON), proteins that are common causes of human cancer and were previously considered undruggable.
  • Specifically, it describes the creation of innovative, natural product-inspired, orally bioavailable small molecules, including the tool compound RMC-4998 and the clinical candidate RMC-6291.
  • Revolution Medicines is currently evaluating RMC-6291 as monotherapy in a Phase 1/1b trial in patients with advanced KRASG12C mutant solid tumors ( NCT05462717 ).

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Tissue, TNBC, DNA, AACR, Liver disease, Cell death, Therapy, CRC, Phosphorylation, CPT, HER2, PALO, Cancer, Traffic barrier, NSCLC, SMDC, Integrin, Lung, Colon, Protein, DNA repair, Partial, Patient, NE, Mouse Models of Human Cancer database, Irinotecan, TME, CRS, ADC, Neoplasm, Poster, Tumor microenvironment, Camptothecin, Breast cancer, Vaccine, Medical imaging, PDX

VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer.

Key Points: 
  • VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer.
  • VIP236 binds to activated αVβ3 integrin, allowing specific homing to the tumor, and is efficiently cleaved by neutrophil elastase (NE).
  • Both proteins are present in the tumor microenvironment (TME), are highly expressed in advanced metastatic tumors, and are associated with poor prognosis.
  • Anticancer activity occurs after a specific and targeted release of an optimized CPT payload by NE in the TME.

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Friday, April 14, 2023
Tumor-associated macrophage, Abstract (summary), AACR, BCL9, Therapy, Clinical trial, Cancer, American Association for Cancer Research, Immunity, Research, Tams, WNT, Trial of the century, CD8, MDSC, Patient, Mouse Models of Human Cancer database, FDA, TIME, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenotype, M1, Food, Pharmaceutical industry, Vaccine, Medical imaging, Wisdom

HARRISON, N.Y., April 14, 2023 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today the presentation of two late-breaking research posters during the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • "We are thrilled to showcase late-breaking results at this year's AACR meeting with data from our ST101 and ST316 programs that address difficult-to-drug cancer targets, C/EBPβ and β-catenin," said Dr. Barry Kappel, founder, CEO and President of Sapience.
  • ST101 is a first-in-class antagonist of C/EBPβ that has demonstrated clinical proof-of-concept in advanced solid tumors.
  • The data support a novel, macrophage-driven mechanism of action for ST101 and suggest the exploration of ST101 in I/O therapeutic strategies.
  • Abstracts and full session details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR

LYNPARZA Market Drug Insight and Market Forecast 2023 - 2032: Detailed Descriptions of Mechanism of Action, Dosage and Administration and R&D Progress - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Pharmaceutical, Health, Oncology, Mouse Models of Human Cancer database, Clinical trial, PARP, DNA repair, Food, News, DNA, PARP3, Pancreatic cancer, ADP, DDR, Disease, Maintenance, Gene, BRCA2, Research, United Kingdom, Patient, ATM, PARP1, Enzyme, Growth, EU4, HRR, Book, Desmoplastic small-round-cell tumor, PARP2, SWOT, Olaparib, Dietary supplement, Pharmaceutical industry, Vaccine, Medical imaging

The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • "LYNPARZA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LYNPARZA for Pancreatic Cancer in the seven major markets.
  • In the DDR pathways, LYNPARZA is being tested in a range of PARP-dependent tumor types with defects and dependencies.
  • The report provides insights into:
    A comprehensive product overview including the LYNPARZA description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.

Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system

Retrieved on: 
Wednesday, December 21, 2022
NGS, Cancer, Patient, CE, Neoplasm, ESMO, Architecture, Mouse Models of Human Cancer database, Drug combination, TME, Oncology, Congress, Lung, 3D, Research, Medical imaging, EU

The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.

Key Points: 
  • The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.
  • Curesponse is a commercial stage precision oncology start up, maker of the cResponse platform, an AI-driven, functional-genomics drug prioritization technology.
  • The company is collaborating with leading pharma partners, offering cResponse as a more timely and predictive drug development platform.
  • In addition, the cResponse test is CE marked and is routinely reimbursed by private payers in Israel for personalized cancer treatment decision guidance.

Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system

Retrieved on: 
Wednesday, December 21, 2022
NGS, Cancer, Patient, CE, Neoplasm, ESMO, Architecture, Mouse Models of Human Cancer database, Drug combination, TME, Multimedia, Oncology, Congress, Lung, 3D, Research, Medical imaging, EU

The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.

Key Points: 
  • The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.
  • Curesponse is a commercial stage precision oncology start up, maker of the cResponse platform, an AI-driven, functional-genomics drug prioritization technology.
  • The company is collaborating with leading pharma partners, offering cResponse as a more timely and predictive drug development platform.
  • In addition, the cResponse test is CE marked and is routinely reimbursed by private payers in Israel for personalized cancer treatment decision guidance.

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, November 7, 2022
Partnership, Research, Colorectal cancer, Exercise, PD-1, Revolution, Conference, Security (finance), Merck & Co., Forward-looking statement, Pancreatic cancer, Mouse Models of Human Cancer database, Amgen, Attention deficit hyperactivity disorder predominantly inattentive, Helmy Eltoukhy, Drug discovery, U.S. Securities and Exchange Commission, Ras GTPase, CRC, Neoplasm, GAAP, Patient, COVID-19, Mutation, Mirati, Nasdaq, Merck, Webcast, Cancer, SHP2, Terminology, Growth, Phosphorylation, GLOBE, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Lung cancer, D, Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Air cargo, NSCLC, Sanofi

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.

Key Points: 
  • In August 2022, Amgen reported preliminary results from this trial at the IASLC 2022 World Conference on Lung Cancer.
  • During the quarter ended September 30, 2022, the company recorded a non-cash GAAP accounting adjustment that reduced collaboration revenue by $4.6 million.
  • Revolution Medicines will host a webcast this afternoon, November 7, 2022, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

National Cancer Center Is Pleased to Name David Knorr, M.D., Ph.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, October 25, 2022
Science, Health, Oncology, Research, Memorial Sloan Kettering Cancer Center, Duke University Hospital, Therapy, Assistant, National Cancer Center, Woman, Diagnosis, Mouse Models of Human Cancer database, Prostate cancer, Education, Laboratory, Patient, United States Air Force Scientific Advisory Board, Interferon, UPMC Hillman Cancer Center, DNA repair, Research, Rockefeller University, Man, Knorr, Harvard Medical School, Brain, Cancer, University, NCC, Immune system, PAP, Cervical cancer, Immunotherapy, Melanoma, Oncology, City, DNA, Death, Rush University Medical Center, Pharmaceutical industry, Dietary supplement, Immunology

The National Cancer Center is pleased to announce the appointment of David Knorr, M.D., Ph.D ., to its Scientific Advisory Board.

Key Points: 
  • The National Cancer Center is pleased to announce the appointment of David Knorr, M.D., Ph.D ., to its Scientific Advisory Board.
  • We are delighted to welcome Dr. Knorr to our Board, said National Cancer Center Scientific Advisory Board Chair Darrell D. Bigner, M.D., Ph.D., Duke University Medical Center.
  • Dr. Knorr said: National Cancer Center fills a critical gap in cancer research by supporting promising early-stage research from young scientists.
  • National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as a non-profit organization committed to research and education about cancer.

Ozgene and Gen-H partner on Ozgene’s new OzBIG targeted humanization capability

Retrieved on: 
Thursday, July 21, 2022
Health, Stem Cells, Genetics, Other Health, Other Science, Science, Biotechnology, Breeding, Escherichia coli, Genome, BAC, Research, CRO, Drug discovery, Partnership, Gene targeting, Disease, Mouse Models of Human Cancer database, Federal Mediation and Conciliation Service (United States), CRISPR, Gene, Technology, Science, Mouse, Antibiotics

Ozgene and Gen-H are pleased to announce our working partnership supporting Ozgenes new OzBIG capability.

Key Points: 
  • Ozgene and Gen-H are pleased to announce our working partnership supporting Ozgenes new OzBIG capability.
  • Ozgene Pty Ltd is a privately held CRO based in Perth, Australia providing custom genetically engineered mice for academic and commercial researchers worldwide.
  • Gen-H GmbH is a privately held CRO based in Heidelberg, Germany providing genetically engineered bacterial clones and E. coli strains.
  • OzBIG vastly expands the gene set available for humanization by enabling the humanization of 90% of the genes in the mouse genome, compared to 10% with standard gene targeting.